Citadel Advisors
IMCR icon

Citadel Advisors’s Immunocore IMCR Stock Holding History

Citadel Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$568K Buy
+17,900
New +$530K ﹤0.01% 9547
2025
Q4 		– Sell
-8,800
Closed -$320K – 13319
2025
Q3 		$320K Buy
+8,800
New +$299K ﹤0.01% 10208
2025
Q2 		– Sell
-12,700
Closed -$377K – 13717
2025
Q1 		$377K Sell
12,700
-1,300
-9% -$39K ﹤0.01% 9089
2024
Q4 		$413K Sell
14,000
-13,300
-49% -$420K ﹤0.01% 8976
2024
Q3 		$850K Sell
27,300
-5,600
-17% -$204K ﹤0.01% 7187
2024
Q2 		$1.11M Sell
32,900
-16,600
-34% -$847K ﹤0.01% 6368
2024
Q1 		$3.22M Buy
49,500
+31,500
+175% +$2.16M ﹤0.01% 4657
2023
Q4 		$1.23M Sell
18,000
-10,300
-36% -$535K ﹤0.01% 6282
2023
Q3 		$1.47M Buy
28,300
+13,300
+89% +$787K ﹤0.01% 5811
2023
Q2 		$899K Sell
15,000
-2,200
-13% -$126K ﹤0.01% 6678
2023
Q1 		$850K Buy
17,200
+6,000
+54% +$337K ﹤0.01% 7146
2022
Q4 		$639K Buy
11,200
+6,200
+124% +$349K ﹤0.01% 7733
2022
Q3 		$235K Sell
5,000
-2,300
-32% -$110K ﹤0.01% 10082
2022
Q2 		$272K Buy
+7,300
New +$237K ﹤0.01% 10021

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors's IMCR Position: Q2 2026 in Review

Citadel Advisors increased its Immunocore (IMCR) stake by 146% in Q2 2026, buying an estimated $9.95M and bringing the position to 566,761 shares worth $18M. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Citadel Advisors first reported a position in IMCR in Q1 2021 and has held it in 22 quarters since. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Citadel Advisors held 566,761 shares of Immunocore worth $18M as of Q2 2026.
  • Citadel Advisors bought 336,362 Immunocore shares in Q2 2026, an estimated $9.95M.
  • Immunocore made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2728 holding.
  • Citadel Advisors first reported a position in Immunocore in Q1 2021 and has held it in 22 quarters since.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.